Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer.

By A. Sandler, J. Nemunaitis, C. Denham, J. Pawel, Y. Cormier, U. Gatzemeier, K. Mattson, C. Manegold, M. Palmer, A. Gregor and 3 more. Journal of Clinical Oncology, 2000

737 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/f62f066f235bea68f89676763548282a2d051f9b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. David H. Johnson
2. C. Azzoli
3. Sherman Baker
4. Thomas J. Smith
5. J. Olak
6. W. Sause
7. John R. Strawn
8. D. Pfister

Citations in the corpus

• American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. (2004, background): “Much of the data suggest that the newer regimens provide higher response rates and longer survival times than single agent cisplatin, or first-generation cisplatinbased regimens [116-126].”